KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Other Non-Current Liabilities: 2009-2024

Historic Other Non-Current Liabilities for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to $4.0 billion.

  • Teva Pharmaceutical Industries' Other Non-Current Liabilities fell 15.65% to $3.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 billion, marking a year-over-year decrease of 15.65%. This contributed to the annual value of $4.0 billion for FY2024, which is 0.22% up from last year.
  • Per Teva Pharmaceutical Industries' latest filing, its Other Non-Current Liabilities stood at $4.0 billion for FY2024, which was up 0.22% from $4.0 billion recorded in FY2023.
  • Teva Pharmaceutical Industries' 5-year Other Non-Current Liabilities high stood at $4.0 billion for FY2024, and its period low was $2.2 billion during FY2020.
  • Its 3-year average for Other Non-Current Liabilities is $4.0 billion, with a median of $4.0 billion in 2023.
  • Per our database at Business Quant, Teva Pharmaceutical Industries' Other Non-Current Liabilities decreased by 15.15% in 2020 and then skyrocketed by 53.03% in 2022.
  • Yearly analysis of 5 years shows Teva Pharmaceutical Industries' Other Non-Current Liabilities stood at $2.2 billion in 2020, then increased by 15.09% to $2.6 billion in 2021, then surged by 53.03% to $3.9 billion in 2022, then increased by 1.88% to $4.0 billion in 2023, then rose by 0.22% to $4.0 billion in 2024.